Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company ...

A new light-based sensor can spot incredibly tiny amounts of cancer biomarkers in blood, raising the possibility of earlier ...

Pharma R&D is shifting to platform models, enhancing efficiency and innovation, as highlighted in EY-Parthenon India's report ...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial ...

EY-Parthenon India on Tuesday unveiled its latest report, “Pharma’s New Architecture: Where Novel Science Meets AI and ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...

A new CRISPR-powered light sensor can detect the faintest whispers of cancer in a single drop of blood.

Author Gabriel Rosenberg advocates that the structure of industrial food production and distribution is key to achieving the best nutrition and food security. The post ‘Feed the People' looks to ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through AI-enhanced computational chemistry, today announced that it will ...

Researchers have developed a highly sensitive light-based sensor that can detect extremely low concentrations of cancer ...

A new highly sensitive light-based sensor can detect extremely low concentrations of cancer biomarkers in the blood.

Sphinx, the company building browser-native compliance agents for financial institutions, today announced it has raised a ...